Gables Capital Management Inc. purchased a new stake in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,302 shares of the company’s stock, valued at approximately $2,095,000.
Merck KGaA Stock Performance
Shares of MKGAF opened at $160.21 on Wednesday. The stock has a market capitalization of $20.71 billion, a PE ratio of 24.46 and a beta of 0.96. The business’s fifty day moving average price is $162.32 and its 200 day moving average price is $148.21. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. Merck KGaA has a 12-month low of $116.68 and a 12-month high of $175.56.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Recommended Stories
- Five stocks we like better than Merck KGaA
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
